Conditions: Subfoveal Choroidal Neovascularization Age-Related Maculopathy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 4
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration

Detailed description:

Arms:
arm 1: Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye arm 2: Intravitreal injection of ranibizumab and Sham into study eye

Interventions: intervention 1: 700 ug dexamethasone intervention 2: ranibizumab intervention 3: sham
Intervention descriptions: intervention 1: Intravitreal injection of 700 ug dexamethasone into study eye intervention 2: Intravitreal injection of ranibizumab into study eye intervention 3: Sham needle-less injection administered in the study eye

Protocol document: